National Institute of Allergy and Infectious Diseases (NIAID)
Who can join
Eligibility, any sex, with Coronavirus Disease 2019 (COVID-19) or SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance PeriodPrimary· Baseline through end of study (24 or 28 weeks, depending on if a participant agreed to do the extension)
Nasal samples were analyzed to determine whether a participant ever tested positive for SARS-CoV-2 or not over the course of the study. Kaplan-Meier was used to estimate survival probabilities at timepoints throughout the study. Participants were censored if they did not test positive for SARS-CoV-2 by the end of follow-up. The last positive nasal swab occurred at day 212.
30 Days
Group
Value
95% CI
Index Participants
98.9
98.4 – 99.1
Non-Index Participants
99.2
98.8 – 99.5
All Participants Combined
99.1
98.8 – 99.4
60 Days
Group
Value
95% CI
Index Participants
98.0
97.3 – 98.8
Non-Index Participants
98.4
97.9 – 98.9
All Participants Combined
98.3
97.9 – 98.7
90 Days
Group
Value
95% CI
Index Participants
97.2
96.3 – 98.1
Non-Index Participants
97.7
97.1 – 98.3
All Participants Combined
97.5
97.0 – 98.0
120 Days
Group
Value
95% CI
Index Participants
95.8
94.7 – 96.9
Non-Index Participants
96.1
95.3 – 96.9
All Participants Combined
96.0
95.3 – 96.6
150 Days
Group
Value
95% CI
Index Participants
94.2
92.9 – 95.6
Non-Index Participants
94.3
93.3 – 95.2
All Participants Combined
94.3
93.5 – 95.1
180 Days
Group
Value
95% CI
Index Participants
90.5
88.5 – 92.7
Non-Index Participants
91.4
90.1 – 92.7
All Participants Combined
91.1
90.0 – 92.2
210 Days
Group
Value
95% CI
Index Participants
90.1
87.9 – 92.4
Non-Index Participants
88.4
85.3 – 91.7
All Participants Combined
89.0
86.8 – 91.3
212 Days
Group
Value
95% CI
Index Participants
90.1
87.9 – 92.4
Non-Index Participants
83.5
77.5 – 89.9
All Participants Combined
85.7
81.5 – 90.1
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected from the time of first procedure, which occurred at study week 2, until a participant completed the study, until 48 hours after he/she prematurely withdrew, or is withdrawn from the study. Participants were followed for 24 or 28 weeks, or until they withdrew..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 presents as a mild to moderate respiratory illness. But it can also be more severe and even lead to death.
The purpose of this study is to:
* Determine the prevalence of SARS-CoV-2 carrier status over time in children and parents
* Determine the prevalence of antibody development over time in children and parents
* Compare carrier status and antibody development for children with asthma and/or other atopic conditions (e.g. eczema) versus children without asthma and/or other atopic conditions
* Investigate the presence of SARS-CoV-2 exposure in historical samples from enrolled participants
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Coronavirus Disease 2019 (COVID-19)
Currently open trials in the same condition.
NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much
· active not recruiting
Other National Institute of Allergy and Infectious Diseases (NIAID) trials
Trials by the same sponsor.
NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV
· Phase 2
· not yet recruiting
NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS)
· Phase 1
· not yet recruiting
NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of
· Phase 1, PHASE2
· not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction
· Phase 1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04375761.